Table 2.

Response Rates According to Baseline Characteristics for Patients With Refractory CLL Treated With Ofatumumab

Baseline Characteristic	FA-ref			BF-ref
	No. of Patients	ORR (%)	P*	No. of Patients	ORR (%)	P*
Age, years
< 65	32	63	.4400	46	48	1.00
≥ 65	27	52		33	45
< 70	49	57	1.00	60	48	.7929
≥ 70	10	60		19	42
Prior rituximab
Yes	35	54	.5984	43	44	.6553
No	24	63		36	50
Prior FCR
Refractory to FCR†	16	50	.5585	16	44	1.00
Other†	43	60		63	48
Prior FC
Refractory to FC‡	33	64	.4264	46	50	.6480
Other‡	26	50		33	42
Palpable lymph node size, cm
≤ 5	43	56	1.00	39	54	.1647
> 5	11	55		36	36
Disease stage
Rai stage I or II	26	58	1.00	24	54	.4654
Rai stage III or IV	32	56		55	44
ECOG PS
0-1	46	59	1.00	66	50	.2384
2	12	58		13	31
FISH cytogenetic abnormalities§
17p del	17	41	.1429	14	14	.0073
No 17p del	40	65		62	55
11q del	24	63	.5963	22	64	.0838
No 11q del	33	55		56	41
12q trisomy	3	33	.5669	8	38	.7147
No 12q trisomy	54	59		70	49

Abbreviations: CLL, chronic lymphocytic leukemia; FA-ref, fludarabine and alemtuzumab refractory; BF-ref, bulky fludarabine refractory; ORR, overall response rate; FCR, fludarabine plus cyclophosphamide and rituximab; FC, fludarabine plus cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; PS, performance status; FISH, fluorescent in situ hybridization.

^*Two-sided Fisher's exact test.

^†Patients considered refractory to FCR, with or without other drugs; other represents patients refractory to a fludarabine-based regimen other than that containing FCR.

^‡Patients considered refractory to FC, with or without other drugs; other represents patients refractory to a fludarabine-based regimen other than that containing FC.

^§Categories adapted from Döhner hierarchical classification of FISH cytogenetic abnormalities.²⁷